Breaking News
April 24, 2019 - Older kidney disease patients starting dialysis die at higher rates than previously thought
April 24, 2019 - Time-restricted eating shows promise for controlling blood glucose levels
April 24, 2019 - Research provides important insight on the brain-body connection
April 24, 2019 - In 10 Years, Half Of Middle-Income Elders Won’t Be Able To Afford Housing, Medical Care
April 24, 2019 - Researchers study how E. coli clones have become major cause of drug-resistant infections
April 24, 2019 - Bacterial and fungal toxins found in popular electronic cigarettes
April 24, 2019 - Texting helps improve medication adherence, health outcomes for patients with schizophrenia
April 24, 2019 - Cochrane Review looks at different ways to use nicotine replacement therapies
April 24, 2019 - New review on relationship between COPD and Type 2 diabetes
April 24, 2019 - Brain areas linked to memory and emotion aid odor navigation in humans
April 24, 2019 - Brain stimulation reverses age-related memory loss
April 24, 2019 - Amid Opioid Prescriber Crackdown, Health Officials Reach Out To Pain Patients
April 24, 2019 - $4 million NIH award will help establish UCI Skin Biology Resource-based Center
April 24, 2019 - Cancer drugs reprogram genes in breast tumors to prevent endocrine resistance, finds study
April 24, 2019 - Combination-imaging technique provides new window into macaque brain connections
April 24, 2019 - Researchers identify new allergen responsible for allergy to durum wheat
April 24, 2019 - Researchers define role of rare, influential cells in the bone marrow
April 24, 2019 - DNA rearrangement may predict poor outcomes in multiple myeloma
April 24, 2019 - FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
April 24, 2019 - Combination therapy might be beneficial in schizophrenia
April 24, 2019 - Blood test can help match cancer patients to early phase clinical trials
April 24, 2019 - Women tend to underreport snoring and underestimate its loudness
April 24, 2019 - Comprehensive molecular test introduced for diagnosis of malaria caused by P. vivax parasites
April 24, 2019 - New range prediction approach increases accuracy, safety and tolerability of proton therapy
April 24, 2019 - Need for Sedation Up for Regular Cannabis Users
April 24, 2019 - Lack of access to antibiotics is a major global health challenge
April 24, 2019 - New study provides better understanding on safety of deworming programs
April 24, 2019 - EEG used to detect impact of maternal stress on neurodevelopment in 2-month-old infants
April 24, 2019 - FDA Approves First Generic Naloxone Nasal Spray Against Opioid Overdose
April 24, 2019 - A new way of finding compounds that prevent aging
April 24, 2019 - Mechanical training makes synthetic hydrogels perform more like muscle
April 24, 2019 - Study provides new insights into regulatory T cells’ role in protecting against autoimmune disease
April 24, 2019 - Pregnant women with type 1 diabetes are at greater risk of preterm birth
April 24, 2019 - ‘Tummy tuck’ can be safely performed in obese patients with no increase in complications
April 23, 2019 - ‘First’ 3-D print of heart with human tissue, vessels unveiled
April 23, 2019 - Which blood-based method works best to detect TB?
April 23, 2019 - Gene therapy cures infants suffering from ‘bubble boy’ immune disease
April 23, 2019 - Chemical-sampling wristbands detect similar exposures across three continents
April 23, 2019 - Management of Residual Limb Pain
April 23, 2019 - Molecular clock influences immune cell responses
April 23, 2019 - On the importance of culture, partnerships and diversity at the Dean’s Lecture Series
April 23, 2019 - Siddhartha Mukherjee Receives Lewis Thomas Prize for Writing About Science
April 23, 2019 - Dengue mosquito poses greatest danger of spreading Zika virus in Australia
April 23, 2019 - Scientists identify 104 high-risk genes for schizophrenia
April 23, 2019 - Abdominal etching can help patients to get classic ‘six-pack abs’ physique
April 23, 2019 - Alvogen Inc. Issues Voluntary Nationwide Recall of Fentanyl Transdermal System Due to Product Mislabeling
April 23, 2019 - Skype hypnotherapy is effective treatment for IBS
April 23, 2019 - The future hope of “flash” radiation cancer therapy
April 23, 2019 - Bicycling, Recycling, and Beyond: Public Safety to Host Shred Fest and Bike-to-Campus Day 
April 23, 2019 - Skipping breakfast linked with increased risk of death from heart disease
April 23, 2019 - Neuroscientists propose new theory about amyloid precursor protein connection in Alzheimer’s
April 23, 2019 - Mediterranean diet protects against overeating and obesity
April 23, 2019 - NUS scientists uncover novel biomarkers linked with ‘chemobrain’
April 23, 2019 - Novel ECCITE-seq technique expands multimodal single cell analysis
April 23, 2019 - Half of all American workplaces offer health and wellness programs
April 23, 2019 - Hypnosis may offer a genuine alternative to painkillers
April 23, 2019 - Sleep loss greatly interferes with job performance
April 23, 2019 - Study shows how elderberry fruit can help fight against influenza
April 23, 2019 - Parkinson’s sufferers regain mobility with new implant
April 23, 2019 - Perinatal Complications Tied to Childhood Social Anxiety
April 23, 2019 - Research reveals how immune cells help tumors escape body’s defenses
April 23, 2019 - UAB receives $17 million grant to explore immune cells in inaccessible tissues of the human body
April 23, 2019 - Opening blocked arteries may be lifesaver for older heart attack patients
April 23, 2019 - Yposkesi chairman to speak on ‘Manufacturing and the CDMO Perspective’ at Cell and Gene Meeting
April 23, 2019 - Listeria Outbreak Linked to Deli Meats, Cheeses in 4 States
April 23, 2019 - Scientists find another way HIV can hide from vaccines
April 23, 2019 - Improved WIC food packages reduced obesity risk for children, study finds
April 23, 2019 - EU ban on ‘meaty’ names for veggie food products would affect public sector
April 23, 2019 - KNAUER self-tests gender pay gap one month after Equal Pay Day
April 23, 2019 - Johns Hopkins study reports overdiagnosis of schizophrenia
April 23, 2019 - New approach to repair defects in fetal membranes could prevent life-long medical conditions
April 23, 2019 - Reviving the heart’s regenerative capacities using microRNAs
April 23, 2019 - New pediatric blood pressure guidelines can better predict kids at higher risk of heart disease
April 23, 2019 - Second HIV remission patient rekindles cure hope
April 23, 2019 - Sparse Treatment Options Complicate Cancer Care For Immigrants In South Texas
April 23, 2019 - Hole-forming protein could help control cancer growth
April 23, 2019 - Study examines factors associated with low use of hearing aids among older Hispanic/Latino adults
April 23, 2019 - Changes to Medicare rules could support care innovation for dialysis
April 23, 2019 - Cancer patients requiring emergency department care have better outcomes at original hospital
April 23, 2019 - Potential of liquid biopsy in cancer biomarker detection and prenatal testing
Parkinson’s disease experts devise a roadmap

Parkinson’s disease experts devise a roadmap

image_pdfDownload PDFimage_print
Parkinson's disease experts devise a roadmap
Key stages of therapeutic discovery and development and associated objectives aimed at improving the probability of technical success. Note the specific utility of biomarkers to inform preclinical and clinical decisions during each stage. DMPK, drug metabolism and pharmacokinetics; ID, identification; PK, pharmacokinetics; PoC, proof of concept; PoM, proof of mechanism; TE, target engagement. Credit: Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Ill.

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson’s disease (PD). Experts in the field of Parkinson’s research have now proposed a roadmap for preclinical and clinical trials investigating compounds targeting alpha-synuclein. Their consensus white paper is published in the Journal of Parkinson’s Disease.

Alpha-synuclein is of key interest to PD researchers because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of PD, and mutations in the gene that encodes alpha-synuclein cause PD. Not surprisingly, intensive efforts have been underway to study the normal and pathological role of alpha-synuclein as well as its potential as a target for neuroprotective therapies. There are at least five alpha-synuclein—targeted therapeutics currently under investigation. These have the potential to slow or arrest the progression of PD and other synucleinopathies, such as Dementia with Lewy Bodies, Multiple System Atrophy and Pure Autonomic Failure.

“With alpha-synuclein undoubtedly playing some role in PD pathogenesis, and there being such a diverse portfolio of experimental therapies that target the protein, one can be optimistic and hope that one of the approaches will eventually be successful in slowing disease progression,” says Patrik Brundin, MD, Ph.D., Associate Director of Research, Professor and Director of the Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, and Co-Editor-in-Chief of the Journal of Parkinson’s Disease.

In 2017, The Michael J. Fox Foundation convened the Alpha Synuclein Clinical Path Working Group comprised of PD research leaders from across academia and industry. This group was tasked to develop a strategic consensus and make recommendations in preclinical and clinical research directed at alpha-synuclein—targeted therapies for PD.

In this consensus white paper, experts provide a translational framework of de-risking the development of alpha-synuclein—targeted therapies. Specifically, the paper discusses the use of fit-for purpose animal models, biomarkers that inform clinical trial design, such as doses and dosing regimen, as well as patient enrichment strategies. Finally, the authors discuss considerations for the design of clinical proof of concept trials that integrate not only pathophysiologic endpoints, but also the emerging technology of wearable devices to monitor clinical outcomes.

“Multiple therapeutics have recently entered clinical trials, and critical human data that will inform all alpha-synuclein—based therapeutic development programs are on the horizon,” says lead author Kalpana M. Merchant, Ph.D., of Vincere Biosciences, Inc. and the Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL. “Although these efforts face many profound challenges, including the lack of key tools such as an alpha-synuclein—based imaging agent and the inherent difficulty of demonstrating clinical efficacy in slowly progressive neurodegenerative diseases, we remain optimistic that meaningful strides toward the ultimate identification and approval of alpha-synuclein—based disease-modifying therapeutics will be made in the near future.”

PD is the second most common neurodegenerative disorder, affecting approximately 1.2 percent of the world population over the age of 70. Although several new therapies that address motor or non-motor symptoms of PD have been approved, none of these are able to slow disease progression. In the US alone, an estimated 630,000 people had PD in 2010. With anticipated demographic changes due to an aging population, and if no disease-modifying treatment is found, the prevalence is expected to reach 930,000 by 2020 and 1.24 million 40 by 2030.


Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease


More information:
Kalpana M. Merchant et al, A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein, Journal of Parkinson’s Disease (2018). DOI: 10.3233/JPD-181471


Provided by
IOS Press

Citation:
Parkinson’s disease experts devise a roadmap (2018, December 20)
retrieved 20 January 2019
from https://medicalxpress.com/news/2018-12-parkinson-disease-experts-roadmap.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Tagged with:

About author

Related Articles